分子イメージングの世界市場

分子イメージングの世界市場は2030年までに104億米ドルに達する

2024年に86億米ドルと推定される分子イメージングの世界市場は、2024年から2030年にかけてCAGR 3.3％で成長し、2030年には104億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである単一光子放出コンピュータ断層撮影法（Single Photon Emission Computed Tomography Modality）は、CAGR 3.3％を記録し、分析期間終了までに46億米ドルに達すると予測されています。陽電子放射断層撮影法（Positron Emission Tomography Modality）セグメントの成長率は、分析期間中CAGR 4.1％と推定されます。

米国市場は23億米ドル、中国はCAGR6.1％で成長すると予測

米国の分子イメージング市場は2024年に23億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを6.1%として、2030年までに21億米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.3％と2.5％と予測されています。欧州では、ドイツがCAGR 1.9%で成長すると予測されています。

世界の分子イメージング市場- 主要動向と促進要因のまとめ

分子イメージングは精密医療と早期疾病発見にどのような革命をもたらしているか？

分子イメージングは、分子および細胞レベルでの生物学的プロセスに対する比類ない洞察を提供する、現代のヘルスケアにおける基礎技術として登場しました。分子イメージングは、主に解剖学的構造に焦点を当てた従来の画像診断とは異なり、機能的・代謝的な情報を提供することで、疾患の早期発見、病期分類、個人に合わせた治療計画の立案に役立ちます。がん、心血管疾患、神経変性疾患などの慢性疾患の増加により、より正確な診断ツールの必要性が高まっています。陽電子放出断層撮影法（PET）、単一光子放出コンピュータ断層撮影法（SPECT）、およびPET-CTやPET-MRIのようなハイブリッドイメージング技術は、疾患の進行や治療反応をリアルタイムで追跡することを可能にし、診断ワークフローを変革してきました。標的画像診断のバイオマーカーとなる放射性医薬品の統合が進み、診断精度と患者の転帰がさらに向上しています。非侵襲的な早期発見法の需要が高まる中、病院、研究機関、製薬業界において分子イメージングは広く採用され続けており、精密医療における極めて重要な役割を担っています。

分子イメージング市場を牽引する技術的進歩とは？

分子イメージング市場は、画像モダリティ、人工知能（AI）、放射性医薬品の継続的な進歩によって急速な変貌を遂げています。AIを活用した画像解析は、複雑な画像データをより迅速かつ正確に解釈することを可能にし、診断ミスを減らし、臨床上の意思決定を改善しています。さらに、特定のバイオマーカーを標的とした新規放射性薬剤の開発により、分子イメージング技術の感度と特異性が大幅に向上しました。PET-CTやSPECT-CTなどのハイブリッド・イメージング・システムは、1回のスキャンで機能的・解剖学的な洞察を統合的に提供することで、診断の状況をさらに洗練させ、効率と患者の快適性を向上させています。光学および蛍光ベースの分子イメージングの台頭は、腫瘍学や神経学における応用を拡大し、研究者が分子活動をリアルタイムで可視化することを可能にしています。さらに、小型化され携帯可能な分子イメージングデバイスは、特に資源が限られた環境でのポイントオブケア診断を容易にするために開発されています。技術が進化し続ける中、AI、機械学習、次世代画像診断薬の融合が分子イメージング市場を再定義し、疾病管理と治療の最適化に新たな可能性をもたらすと期待されています。

規制と市場力学は分子イメージングの採用にどのような影響を与えているか？

規制の枠組みや市場力学は、分子イメージング分野の成長を形成する上で重要な役割を果たしています。放射性医薬品やイメージングデバイスの承認と流通を管理する厳しいガイドラインは、安全性と有効性の基準を満たすための継続的な技術革新を必要とします。米国食品医薬品局（FDA）や欧州医薬品庁（EMA）などの機関は、分子イメージング技術の信頼性と倫理的使用を保証するため、厳格なコンプライアンス対策を課しています。同時に、政府、ヘルスケア機関、民間団体による投資の増加が、この分野における研究開発のイニシアチブを後押ししています。官民パートナーシップの動向は、新興国における分子イメージングインフラの拡大を促進し、高度な診断サービスへのアクセスを広げています。さらに、画像診断に対する償還政策は市場導入に大きな影響を与え、有利な償還モデルはより広範な臨床利用を促しています。さらに、製薬業界は医薬品開発と臨床試験において分子イメージングに依存しており、この分野の市場開発の可能性を高めています。規制状況が進化し続ける中、市場成長を維持し、分子イメージングソリューションのアクセシビリティを拡大するためには、イノベーションをコンプライアンスに適合させることが不可欠です。

分子イメージング市場の成長を促進する主な要因は？

世界の分子イメージング市場の成長は、疾病負担の増加、技術の進歩、規制支援、研究投資の増加など、いくつかの要因によって促進されています。がん、心血管系疾患、神経疾患の発生率の増加により、早期かつ正確な診断の必要性が高まっており、分子イメージングは現代ヘルスケアにおける重要なツールとなっています。放射性医薬品、AIを活用した画像解析、ハイブリッド画像システムの革新により、診断精度が大幅に向上し、医療・研究用途での採用が広がっています。また、個別化医療や標的治療アプローチの拡大も、個々の患者プロファイルに基づくオーダーメイドの治療戦略を可能にするため、分子イメージングの需要を押し上げています。さらに、新興国における医療費の増加やイメージング・インフラの拡大が、十分なサービスを受けていない地域への市場浸透を促進しています。製薬・バイオテクノロジー業界が創薬、バイオマーカー検証、臨床試験モニタリングのために分子イメージングに依存していることも、主要な成長加速要因の一つです。さらに、非侵襲的イメージング技術や次世代トレーサーの研究が進むことで、分子イメージングの応用範囲が拡大すると予想されます。世界中のヘルスケアシステムが疾患の早期発見と精密医療を優先しているため、分子イメージング市場は持続的な拡大が見込まれ、業界の利害関係者や研究者に新たな機会を提供しています。

セグメント

モダリティ（単一光子放出コンピュータ断層撮影モダリティ、陽電子放出断層撮影モダリティ、核磁気共鳴スペクトロメーターモダリティ、分子超音波イメージングモダリティ、その他のモダリティ）、用途（腫瘍学用途、心臓血管用途、神経学用途、呼吸器用途、その他の用途）、最終用途（病院最終用途、画像診断センター最終用途、研究機関最終用途）

調査対象企業の例

• Abbott Laboratories
• Bio-Rad Laboratories
• Bruker Corporation
• Canon Medical Systems Corporation
• Cubresa Inc.
• Esaote
• GE HealthCare
• Koninklijke Philips N.V.
• Mediso
• PerkinElmer
• PerkinElmer Inc.
• Positron Corporation
• QIAGEN
• Roche Diagnostics
• Shimadzu Corporation
• Siemens AG
• Siemens Healthineers
• Thermo Fisher Scientific
• United Imaging Healthcare Co.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Molecular Imaging Market to Reach US$10.4 Billion by 2030

The global market for Molecular Imaging estimated at US$8.6 Billion in the year 2024, is expected to reach US$10.4 Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2024-2030. Single Photon Emission Computed Tomography Modality, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$4.6 Billion by the end of the analysis period. Growth in the Positron Emission Tomography Modality segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.3 Billion While China is Forecast to Grow at 6.1% CAGR

The Molecular Imaging market in the U.S. is estimated at US$2.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 6.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global Molecular Imaging Market - Key Trends & Drivers Summarized

How Is Molecular Imaging Revolutionizing Precision Medicine and Early Disease Detection?

Molecular imaging has emerged as a cornerstone technology in modern healthcare, offering unparalleled insights into biological processes at the molecular and cellular levels. Unlike traditional imaging modalities that primarily focus on anatomical structures, molecular imaging provides functional and metabolic information that aids in early disease detection, staging, and personalized treatment planning. The rising prevalence of chronic diseases such as cancer, cardiovascular disorders, and neurodegenerative conditions has intensified the need for more precise diagnostic tools. Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), and hybrid imaging techniques such as PET-CT and PET-MRI have transformed diagnostic workflows by enabling real-time tracking of disease progression and treatment response. The growing integration of radiopharmaceuticals, which serve as biomarkers for targeted imaging, is further enhancing diagnostic accuracy and patient outcomes. As the demand for non-invasive and early detection methods rises, molecular imaging continues to gain widespread adoption across hospitals, research institutions, and pharmaceutical industries, reinforcing its pivotal role in precision medicine.

What Technological Advancements Are Driving the Molecular Imaging Market?

The molecular imaging market is witnessing a rapid transformation, driven by continuous advancements in imaging modalities, artificial intelligence (AI), and radiopharmaceuticals. AI-powered imaging analytics have enabled faster and more precise interpretation of complex imaging data, reducing diagnostic errors and improving clinical decision-making. Additionally, the development of novel radiotracers targeting specific biomarkers has significantly enhanced the sensitivity and specificity of molecular imaging techniques. Hybrid imaging systems, such as PET-CT and SPECT-CT, have further refined the diagnostic landscape by providing integrated functional and anatomical insights in a single scan, thereby improving efficiency and patient comfort. The rise of optical and fluorescence-based molecular imaging is expanding applications in oncology and neurology, enabling researchers to visualize molecular activity in real-time. Moreover, miniaturized and portable molecular imaging devices are being developed to facilitate point-of-care diagnostics, particularly in resource-limited settings. As technology continues to evolve, the convergence of AI, machine learning, and next-generation imaging agents is expected to redefine the molecular imaging market, unlocking new possibilities for disease management and treatment optimization.

How Is Regulatory and Market Dynamics Influencing Molecular Imaging Adoption?

Regulatory frameworks and market dynamics play a crucial role in shaping the growth of the molecular imaging sector. Stringent guidelines governing the approval and distribution of radiopharmaceuticals and imaging devices necessitate continuous innovation to meet safety and efficacy standards. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have imposed rigorous compliance measures to ensure the reliability and ethical use of molecular imaging technologies. At the same time, increasing investments from governments, healthcare institutions, and private entities are driving research and development initiatives in this space. The growing trend of public-private partnerships is facilitating the expansion of molecular imaging infrastructure in emerging economies, broadening access to advanced diagnostic services. Additionally, reimbursement policies for imaging procedures significantly impact market adoption, with favorable reimbursement models encouraging wider clinical utilization. Furthermore, the pharmaceutical industry's reliance on molecular imaging for drug development and clinical trials is reinforcing the sector’s market potential. As regulatory landscapes continue to evolve, aligning innovation with compliance will be essential in sustaining market growth and expanding the accessibility of molecular imaging solutions.

What Are the Key Factors Fueling the Growth of the Molecular Imaging Market?

The growth in the global molecular imaging market is driven by several factors, including rising disease burden, technological advancements, regulatory support, and increasing research investments. The growing incidence of cancer, cardiovascular diseases, and neurological disorders has amplified the need for early and accurate diagnosis, positioning molecular imaging as a critical tool in modern healthcare. Innovations in radiopharmaceuticals, AI-driven imaging analytics, and hybrid imaging systems have significantly enhanced diagnostic precision, leading to wider adoption across medical and research applications. The expansion of personalized medicine and targeted therapy approaches is also boosting demand for molecular imaging, as it enables tailored treatment strategies based on individual patient profiles. Additionally, increasing healthcare expenditures in emerging economies and the expansion of imaging infrastructure are driving market penetration in underserved regions. The pharmaceutical and biotechnology industries' dependence on molecular imaging for drug discovery, biomarker validation, and clinical trial monitoring is another key growth accelerator. Moreover, ongoing research into non-invasive imaging techniques and next-generation tracers is expected to expand the scope of molecular imaging applications. As healthcare systems worldwide prioritize early disease detection and precision medicine, the molecular imaging market is poised for sustained expansion, offering new opportunities for industry stakeholders and researchers alike.

SCOPE OF STUDY:

The report analyzes the Molecular Imaging market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Modality (Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality, Other Modalities); Application (Oncology Application, Cardiovascular Application, Neurology Application, Respiratory Application, Other Applications); End-Use (Hospitals End-Use, Diagnostic Imaging Centers End-Use, Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

• Abbott Laboratories
• Bio-Rad Laboratories
• Bruker Corporation
• Canon Medical Systems Corporation
• Cubresa Inc.
• Esaote
• GE HealthCare
• Koninklijke Philips N.V.
• Mediso
• PerkinElmer
• PerkinElmer Inc.
• Positron Corporation
• QIAGEN
• Roche Diagnostics
• Shimadzu Corporation
• Siemens AG
• Siemens Healthineers
• Thermo Fisher Scientific
• United Imaging Healthcare Co.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Molecular Imaging - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Prevalence of Chronic Diseases Accelerates Demand for Advanced Molecular Imaging Techniques
  • Advancements in Nuclear Medicine Fuel Growth in PET and SPECT Imaging Modalities
  • Growing Focus on Personalized Medicine Expands Market Opportunities for Targeted Molecular Imaging
  • Surge in Oncology Research and Clinical Trials Boosts Adoption of Molecular Imaging in Cancer Detection
  • Technological Innovations in Imaging Agents Enhance the Accuracy and Efficiency of Molecular Imaging Procedures
  • Increasing Demand for Non-invasive Diagnostic Techniques Drives Adoption of Molecular Imaging in Healthcare
  • Growing Aging Population Spurs Demand for Early Disease Detection and Monitoring Solutions
  • Rising Popularity of Biomarker Discovery and Development Fuels Demand for Molecular Imaging Technologies
  • Integration of Artificial Intelligence and Machine Learning into Molecular Imaging Systems Enhances Diagnostic Capabilities
  • Expansion of Healthcare Infrastructure in Emerging Markets Expands Addressable Market Opportunity for Molecular Imaging
  • Growing Focus on Early Disease Detection Strengthens Business Case for Molecular Imaging Technologies
  • Regulatory Advancements in the Approval of Novel Imaging Agents Propel Growth in the Molecular Imaging Market
  • Government Initiatives and Funding for Medical Research Drive Innovation in Molecular Imaging Techniques
  • Development of Radiopharmaceuticals and Novel Imaging Probes Opens New Avenues for Molecular Imaging Applications
  • Increasing Collaboration Between Biopharmaceutical Companies and Imaging Device Manufacturers Spurs Market Growth
  • Rising Healthcare Expenditure and Investment in Diagnostic Imaging Systems Support Demand for Molecular Imaging Solutions
  • Growing Interest in Cardiovascular Disease Management Drives Adoption of Molecular Imaging for Early Diagnosis and Risk Assessment
  • Integration of Molecular Imaging with Theranostics Strengthens Adoption of Personalized Treatment Plans
  • Pressure to Improve Healthcare Outcomes and Reduce Costs Promotes the Use of Advanced Imaging in Healthcare Facilities
  • Increasing Use of Molecular Imaging in Preclinical Studies Accelerates Demand for Imaging Solutions in Research and Development
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Molecular Imaging Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Molecular Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Molecular Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Molecular Imaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Single Photon Emission Computed Tomography Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Single Photon Emission Computed Tomography Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Single Photon Emission Computed Tomography Modality by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Positron Emission Tomography Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Positron Emission Tomography Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Positron Emission Tomography Modality by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Nuclear Magnetic Resonance Spectrometer Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Nuclear Magnetic Resonance Spectrometer Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Nuclear Magnetic Resonance Spectrometer Modality by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Molecular Ultrasound Imaging Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Molecular Ultrasound Imaging Modality by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Molecular Ultrasound Imaging Modality by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Modalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Modalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Modalities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Cardiovascular Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Cardiovascular Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Cardiovascular Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Neurology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Neurology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Neurology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Respiratory Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Respiratory Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Respiratory Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Diagnostic Imaging Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Diagnostic Imaging Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Diagnostic Imaging Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 44: USA Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 50: USA Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• JAPAN
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• CHINA
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 71: China Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• EUROPE
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Molecular Imaging by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Molecular Imaging by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Molecular Imaging by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• FRANCE
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 92: France Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 95: France Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: France Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: France 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 98: France Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: France 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• GERMANY
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 104: Germany Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Germany Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Germany 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Germany 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 113: Italy Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Italy Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Italy 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Italy 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 119: UK Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 122: UK Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: UK Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: UK 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 125: UK Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: UK 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 131: Spain Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Spain Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Spain 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Spain 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 140: Russia Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Russia Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Russia 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Russia 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Rest of Europe Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Rest of Europe 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Imaging by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Molecular Imaging by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Molecular Imaging by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 170: Australia Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Australia Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Australia 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Australia 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• INDIA
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 176: India Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 179: India Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: India Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: India 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 182: India Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: India 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 188: South Korea Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: South Korea Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: South Korea 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: South Korea 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Asia-Pacific Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Molecular Imaging by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Molecular Imaging by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Molecular Imaging by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Latin America 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 218: Argentina Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Argentina Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Argentina 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Argentina 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 227: Brazil Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Brazil Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Brazil 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Brazil 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 236: Mexico Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Mexico Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Mexico 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Mexico 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Latin America Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Latin America 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Molecular Imaging by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Molecular Imaging by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Molecular Imaging by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Middle East 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 266: Iran Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Iran Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Iran 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Iran 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 275: Israel Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Israel Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Israel 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Israel 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Saudi Arabia Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Saudi Arabia 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 293: UAE Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: UAE Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: UAE 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: UAE 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Middle East Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Middle East 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030
• AFRICA
  • Molecular Imaging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Molecular Imaging by Modality - Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Molecular Imaging by Modality - Percentage Breakdown of Value Sales for Single Photon Emission Computed Tomography Modality, Positron Emission Tomography Modality, Nuclear Magnetic Resonance Spectrometer Modality, Molecular Ultrasound Imaging Modality and Other Modalities for the Years 2015, 2025 & 2030
  • TABLE 311: Africa Recent Past, Current & Future Analysis for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Africa Historic Review for Molecular Imaging by Application - Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Africa 15-Year Perspective for Molecular Imaging by Application - Percentage Breakdown of Value Sales for Other Applications, Oncology Application, Cardiovascular Application, Neurology Application and Respiratory Application for the Years 2015, 2025 & 2030
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Molecular Imaging by End-Use - Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Africa 15-Year Perspective for Molecular Imaging by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Imaging Centers End-Use and Research Institutes End-Use for the Years 2015, 2025 & 2030

IV. COMPETITION